Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm IncfiledCriticalBiocryst Pharm Inc
Priority claimed from PCT/US2015/019535external-prioritypatent/WO2015134998A1/en
Publication of MA39719B1publicationCriticalpatent/MA39719B1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Cette invention concerne des composés de formule (i), et leurs sels de qualité pharmaceutique. Les composés sont des inhibiteurs de la kallicréine plasmatique l'invention concerne également des compositions pharmaceutiques comprenant au moins un composé de l'invention, et des procédés impliquant l'utilisation des composés et des compositions de l'invention dans le traitement et la prévention de maladies et de pathologies caractérisées par une activité indésirable de la kallicréine plasmatique.This invention relates to compounds of formula (i), and their pharmaceutical grade salts. The compounds are inhibitors of plasma kallikrein The invention also relates to pharmaceutical compositions comprising at least one compound of the invention, and to methods involving the use of the compounds and compositions of the invention in the treatment and prevention of diseases and pathologies characterized by undesirable activity of plasma kallikrein.
MA39719A2014-03-072015-03-09
Pyrazoles substituted with trifluoromethyl as inhibitors of human plasma kallikrein
MA39719B1
(en)
1h-indazole-3-carboxamide derivatives and similar compounds as d-factor inhibitors for the treatment of diseases characterized by aberrant activity of the complementary system, such as p.E. Immunological disorders